Arcturus Therapeutics this week announced new data showing that its proprietary lipid nanoparticles are capable of functionally delivering messenger RNA into the livers of mice, which a company official said opens the door for the use of the technology with CRISPR-based drugs.

The firm also released rodent and non-human primate data, generated as part of its TTR-mediated amyloidosis (ATTR) program, demonstrating the safety and efficacy of the technology for siRNA delivery.